• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Jul 7;15(1):24224.
doi: 10.1038/s41598-025-06880-3. Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice

Reshma Koolaparambil Mukesh[SUP] 1 [/SUP], Tom Hill[SUP] 2 [/SUP], Franziska Kaiser[SUP] 1 [/SUP], Jessica Prado-Smith[SUP] 3 [/SUP], Jonathan E Schulz[SUP] 1 [/SUP], Shane Gallogly[SUP] 1 [/SUP], Lisa Herbold[SUP] 3 [/SUP], Kaitlyn Bauer[SUP] 3 [/SUP], Brian J Smith[SUP] 3 [/SUP], Lara Myers[SUP] 4 [/SUP], Aaron B Carmody[SUP] 4 [/SUP], Carl Shaia[SUP] 3 [/SUP], Vincent J Munster[SUP] 1 [/SUP], Neeltje van Doremalen[SUP] 5 [/SUP]



Affiliations
Abstract

Vaccines against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are highly effective in preventing severe disease but are less consistent in protecting against infection and transmission. Developing vaccines with enhanced immunogenicity that can provide protection in both the upper and lower respiratory tract (URT and LRT) is crucial. Mucosal immunization induces immunity at the site of initial infection, the respiratory tract, thereby preventing or mitigating infection. Here, we compared immune responses elicited by intramuscular mRNA vaccination alone with those elicited by intramuscular mRNA vaccination followed by intranasal administration of ChAdOx1 nCoV-19 vaccine in mice. Although both vaccination strategies induced strong systemic immunity, robust humoral and cellular mucosal immune responses, including spike-specific IgA and tissue-resident T cells, were only detected upon mucosal vaccination. Compared to unvaccinated animals, mucosal vaccination resulted in migration of T cells and macrophages into the nasal turbinates, as well as migration and proliferation of B and T cells in the nasal-associated lymphoid tissue. While both vaccination regimens provided protection across the entire respiratory tract at 2 weeks post-vaccination, at 12 weeks post-vaccination, only the mice that received a mucosal vaccination remained protected in the URT. Gene-expression profiling of the respiratory tract at 2 days post-infection revealed distinct clustering between groups. Enrichment of immune signaling pathways, including B and T cells receptor pathways, was significantly higher in intranasally vaccinated animals. Together, our study demonstrates that mucosal vaccination provides durable protection against SARS-CoV-2 than intramuscular vaccination alone.


 
Back
Top Bottom